Alexander Bagasra, MD
Infectious Disease · Fairfax, VANPI 1083871800
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 243 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations.
Across 243 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Melinta Therapeutics, LLC$1K
- Viiv Healthcare Company$752
- Insmed, Inc.$569
- Gilead$485
- Merck$460
- Shionogi Inc$455
- plus $2K from 18 others
What the payments were for
- Food & beverage$5,13094%
- Education$3176%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Melinta Therapeutics, LLC | 37 | $1,076 |
| Viiv Healthcare Company | 36 | $752 |
| Insmed, Inc. | 28 | $569 |
| Gilead | 23 | $485 |
| Merck | 22 | $460 |
| Shionogi Inc | 25 | $455 |
| AbbVie(2 entities) | 16 | $384 |
| Johnson & Johnson(2 entities) | 14 | $267 |
| Theratechnologies Inc. | 7 | $179 |
| La Jolla Pharmaceutical Company | 7 | $166 |
| Paratek Pharmaceuticals, Inc. | 7 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $114 |
| Janssen Products, LP | 1 | $55 |
| Astellas Pharma US Inc | 2 | $53 |
| Aimmune Therapeutics, Inc. | 2 | $52 |
| Pfizer | 2 | $48 |
| Napo Pharmaceuticals Inc | 1 | $35 |
| Dynavax Technologies Corporation | 2 | $30 |
| Ferring Pharmaceuticals Inc. | 1 | $29 |
| Smith+Nephew | 2 | $25 |
| Vyera Pharmaceuticals, LLC | 1 | $22 |
| Pharming Healthcare, Inc. | 1 | $22 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,447 in reported general payments places this provider in the 85th percentile of 194 infectious disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErtapenemErtapenem Sodium | 45 | $20,529 |
| Meropenem | 21 | $4,866 |
| Daptomycin | 15 | $4,433 |
| Ampicillin Sodium | 13 | $3,469 |
| CeftriaxoneCeftriaxone Sodium | 30 | $2,077 |
| Vancomycin Hcl | 14 | $1,645 |
| Doxycycline Hyclate | 22 | $1,060 |
| Ethambutol Hcl | 14 | $942 |
| Ciprofloxacin Hcl | 34 | $758 |
| Rifampin | 15 | $643 |
| Azithromycin | 22 | $382 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Fairfax
- Stephen WeinrothFairfax$157K
- Marsha SoniFairfax$12K
- Jane PollnerFairfax$8K
- Trevor UyemuraFairfax$7K
- Vijender BajwaFairfax$4K
- Gelareh AlaviFairfax$691
- Murliya GowdaFairfax$684
- Christopher BettacchiMarion$243K
- William PetriCharlottesville$92K
- Michael IsonFalls Church$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.